- Previous Close
0.0000 - Open
0.0050 - Bid 0.0021 x --
- Ask 0.0085 x --
- Day's Range
0.0050 - 0.0050 - 52 Week Range
0.0001 - 0.0210 - Volume
8,000 - Avg. Volume
0 - Market Cap (intraday)
935,821 - Beta (5Y Monthly) -849.89
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
PsyBio Therapeutics Corp., a biotechnology company, engages in the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. PsyBio Therapeutics Corp. was formerly known as Leo Acquisitions Corp. and changed its name to PsyBio Therapeutics Corp. in January 2021. The company is headquartered in Denver, Colorado.
www.psybiolife.comRecent News: PSYBF
View MorePerformance Overview: PSYBF
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PSYBF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PSYBF
View MoreValuation Measures
Market Cap
12.75k
Enterprise Value
96.52k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-209.00%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-1.9M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
12.37k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-343.08k